Safety and Efficacy of Adding Fixed-Combination Brinzolamide/Timolol Maleate to Prostaglandin Therapy for Treatment of Ocular Hypertension or Glaucoma
Table 1
Patient experience survey data.
Incidence and severity
Patients, (%)
value
Baseline
Week 12
Do you experience or have you noticed
At this moment
Immediately following instillation of study medication
Pain in or around your eyes when exposed to light?
Yes
5 (10.6)
5 (12.8)
0.753
Minimal
0
1 (20.0)
0.072
Mild
0
1 (20.0)
Moderate
1 (20.0)
3 (60.0)
Severe
4 (80.0)
0
Blurred or dim vision?
Yes
9 (19.2)
14 (35.9)
0.081
Minimal
5 (55.6)
6 (42.9)
0.733
Mild
2 (22.2)
3 (21.4)
Moderate
2 (22.2)
5 (35.7)
Severe
0
0
Stinging or burning?
Yes
14 (29.8)
12 (30.8)
0.921
Minimal
3 (21.4)
7 (53.9)
0.035
Mild
9 (64.3)
2 (15.4)
Moderate
2 (14.3)
4 (30.8)
Severe
0
0
A feeling that something is in your eyes or under your lids?
Yes
11 (23.4)
11 (28.2)
0.611
Minimal
2 (18.2)
4 (40.0)
0.385
Mild
4 (36.4)
4 (40.0)
Moderate
5 (45.5)
2 (20.0)
Severe
0
0
Deep pain in or around your eyes?
Yes
3 (6.4)
3 (7.7)
0.812
Minimal
0
1 (33.3)
0.368
Mild
1 (33.3)
0
Moderate
2 (66.7)
2 (66.7)
Severe
0
0
Redness in your eyes?
Yes
13 (27.7)
11 (28.2)
0.955
Minimal
5 (38.5)
3 (27.3)
0.366
Mild
4 (30.8)
7 (63.6)
Moderate
3 (23.1)
1 (9.1)
Severe
1 (7.7)
0
For each question, the percentage of “yes” responses was calculated based on the group size, and severity data were calculated as the percentage of patients who responded “yes.” Numbers of “yes” responses at week 12 versus baseline were analyzed by 1-way analysis of variance. Symptom severity responses at week 12 versus baseline were analyzed by 1-way analysis of variance. Causes of redness were not specified.
